In The Literature
Blood (ASH Abstract)

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis

Blood (ASH Abstract)

Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms

Blood (ASH Abstract)

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients with Polycythemia Vera

American Journal of Hematology

Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger

European Journal of Haematology

Frequency and Etiology of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

New England Journal of Medicine

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

Blood Advances

The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Polycythemia Vera

Journal of Managed Care & Specialty Pharmacy

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera

Clinical Lymphoma, Myeloma & Leukemia

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States

Cancer Medicine

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Experimental Hematology & Oncology

Are Patients With High-Risk Polycythemia Vera Receiving Cytoreductive Medications? A Retrospective Analysis of Real-World Data

British Journal of Haematology

Pentraxin‐3 Plasma Levels Correlate With Tumour Burden and Overall Survival in Patients With Primary Myelofibrosis

Journal of Hematology & Oncology

Evaluation of an Alternative Ruxolitinib Dosing Regimen in Patients With Myelofibrosis: An Open-Label Phase 2 Study

Journal of Clinical Oncology (ASCO Abstract)

The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant

Journal of Clinical Oncology (ASCO Abstract)

Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: A pilot study


The role of JAK2 inhibitors in MPNs 7 years after approval

Oncology (Williston Park)

Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies

BMC Cancer

Impact of Myeloproliferative Neoplasms on Patients’ Employment Status and Work Productivity in the United States: Results from the Living with MPNs Survey


GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

Medical Science Monitor

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α

Bone Marrow Transplantation

Early Human Cytomegalovirus Reactivation Is Associated With Lower Incidence of Relapse of Myeloproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation

Blood Advances

Targeted Next-Generation Sequencing in Blast Phase Myeloproliferative Neoplasms

European Journal of Haematology

Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey

Blood Advances

Sipa1 deficiency–induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm

Quality of Life Research

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project

Cell Death & Disease

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

European Journal of Haematology

Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms

American Journal of Hematology

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms

Blood Cancer Journal

Polycythemia Vera Treatment Algorithm 2018

Blood Cancer Journal

Essential Thrombocythemia Treatment Algorithm 2018

Cancer Cell

Development of a Targeted Next-Generation Sequencing assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms

Am J Hematol

MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

Blood (ASH Abstract)

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Blood (ASH Abstract)

Revised DIPSS-Plus: A Composite Clinical, Cytogenetic and Molecular Prognostic System for Primary Myelofibrosis

Annals of Internal Medicine

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study

Sci Transl Med

A New Therapeutic Target for Myelofibrosis is Cause for Gli

BMJ Case Rep

Ruxolitinib Treatment in an Infant with JAK2+ Polycythaemia Vera-Associated Budd-Chiari Syndrome

J Cell Mol Med

Epigenetics in Myeloproliferative Neoplasms

Mayo Clin Proc

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome

Am J Hematol

A Re-Appraisal of the Benefit-Risk Profile of Hydroxyurea in Polycythemia Vera: A Propensity-Matched Study

Medicine (Baltimore)

Progression of Primary Myelofibrosis to Polycythemia Vera: A Case Report


Racial and Ethnic Disparities in Hematologic Malignancies

Blood Cancer J

Flow Cytometry-Based Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia from Myeloproliferative Neoplasms With Associated Monocytosis

Radiol Oncol

Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease

Leuk Res

A Phase 2 Study of Momelotinib, a Potent JAK1 and JAK2 inhibitor, in Patients With Polycythemia Vera or Essential Thrombocythemia

Leuk Res

Multicenter Phase 2 Study of Combination Therapy with Ruxolitinib and Danazol in Patients with Myelofibrosis

Cancer Med

Role of Treatment on the Development of Secondary Malignancies in Patients with Essential Thrombocythemia

Ann Hematol

Thromboses and Hemorrhages are Common in MPN Patients with High JAK2V617F Allele Burden

Leuk Res

Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients With Primary Myelofibrosis

Int J Hematol

Administration of Direct Oral Anticoagulants in Patients With Myeloproliferative Neoplasms

Ann Vasc Surg

Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure

Am J Hematol

Multicenter Analysis of the Use of Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Management of MPN-Associated Portal Hypertension


Diagnosis and Classification of Hematologic Malignancies on the Basis of Genetics

Biol Blood Marrow Transplant

Allogeneic Stem Cell Transplantation in Myelofibrosis

Curr Opin Hematol

'JAK-ing' Up the Treatment of Primary Myelofibrosis: Building Better Combination Strategies

Ann Hematol

Ruxolitinib Reduces JAK2 p.V617F Allele Burden in Patients With Polycythemia Vera Enrolled in the RESPONSE Study


Characteristics and Clinical Significance of Cytogenetic Abnormalities in Polycythemia Vera

Br J Haematol

A Retrospective Analysis of the Impact of Treatments and Blood Counts on Survival and the Risk of Vascular Events During the Course of Polycythemia Vera

Int J Lab Hematol

Frequency of Polycythemia in Individuals With Normal Complete Blood Cell Counts According to the New 2016 WHO Classification of Myeloid Neoplasms


JAK2 Inhibitors for Myeloproliferative Neoplasms: What Is Next?

J Theor Biol

Determining the Role of Inflammation in the Selection of JAK2 Mutant Cells in Myeloproliferative Neoplasms

Expert Rev Hematol

Detection of Driver and Subclonal Mutations in Myelofibrosis: Clinical Impact on Pharmacologic and Transplant-Based Treatment Strategies


The Effect of Initial Molecular Profile on Response to Recombinant Interferon-α (rIFNα) Treatment in Early Myelofibrosis

Med Oncol

Targeted Next-Generation Sequencing Identified Novel Mutations in Triple-Negative Myeloproliferative Neoplasms


Enhanced Calreticulin Expression in Red Cells of Polycythemia Vera Patients Harboring the JAK2V617F Mutation

J Clin Invest

Downregulation of GATA1 Drives Impaired Hematopoiesis in Primary Myelofibrosis


Polycythemia Vera Management and Challenges in the Community Health Setting

J Natl Compr Canc Netw

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Intern Med J

A Case-Based Discussion of Clinical Problems in the Management of Patients Treated With Ruxolitinib for Myelofibrosis

Clin Adv Hematol Oncol

Prevention and Management of Thrombosis in Myeloproliferative Neoplasms

Curr Opin Hematol

Management of Venous Thromboembolism in Myeloproliferative Neoplasms


Differences in Treatment Goals and Perception of Symptom Burden Between Patients With Myeloproliferative Neoplasms (MPNs) and Hematologists/Oncologists in the United States: Findings from the MPN Landmark Survey

Leuk Lymphoma

Clinical Use of Ruxolitinib in an Academic Medical Center in Unselected Patients With Myeloproliferative Neoplasms not on Clinical Study

Leuk Res

Markers of Iron Deficiency in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy

Ther Adv Hematol

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Pathophysiology and Molecular Mechanisms of Disease

Biol Blood Marrow Transplant

The Impact of Splenectomy in Myelofibrosis Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Ann Hematol

Novel Hematological Parameters for the Evaluation of Patients With Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions


No Correlation of Intensity of Phlebotomy Regimen With Risk of Thrombosis in Polycythemia Vera: Evidence From ECLAP and CYTO-PV Clinical Trials

Ann Vasc Surg

Medical Management of Extensive Arterial Thromboembolism in a Patient With Essential Thrombocythemia and Warfarin Failure

Blood Cancer J

Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations


Myeloproliferative Neoplasm Stem Cells

J Hematol Oncol

Long-Term Treatment with Ruxolitinib for Patients With Myelofibrosis: 5-Year Update From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial

Br J Haematol

Progenitor Genotyping Reveals a Complex Clonal Architecture in a Subset of CALR-Mutated Myeloproliferative Neoplasms

Blood Cancer J

The Role of the Extracellular Matrix in Primary Myelofibrosis

Br J Haematol

Approach to Patients With Essential Thrombocythemia and Very High Platelet Counts: What is the Evidence for Treatment?

Am J Hematol

Polycythemia Vera and Essential Thrombocythemia: 2017 Update on Diagnosis, Risk-Stratification, and Management

Ann Lab Med

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

J Clin Pathol

A Novel Molecular Assay Using Hybridisation Probes and Melt Curve Analysis for CALR Exon 9 Mutation Detection in Myeloproliferative Neoplasms

Clin Med (Lond)

Myocardial Infarction With Proximal Occlusion of the Left Anterior Descending Coronary Artery in a 22-Year-Old Patient With Polycythaemia Vera


Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes

Nature Scientific Rep

Neutrophil Extracellular Trap Formation and Circulating Nucleosomes in Patients With Chronic Myeloproliferative Neoplasms


Emerging Treatments for Classical Myeloproliferative Neoplasms


Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis

Blood Cancer J

Bone Marrow Fibrosis Grade is an Independent Risk Factor for Overall Survival in Patients With Primary Myelofibrosis

Curr Opin Hematol

'Janus Kinase-ing' Up the Treatment of Primary Myelofibrosis

Int J Lab Hematol

Proliferative Characteristics of Philadelphia-Negative Myeloproliferative Neoplasms: Clinical Implications


Aberrant Let7a/HMGA2 Signaling Activity Associated With Unique Clinical Phenotypes in JAK2-Mutated Myeloproliferative Neoplasms

Ann Hematol

Programmed Cell Death-1 Pathway Inhibition in Myeloid Malignancies: Implications for Myeloproliferative Neoplasms

World J Cardiol

Hematological Disorders and Pulmonary Hypertension

PLoS One

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

Expert Opin Investig Drugs

Investigational Distone Deacetylase Inhibitors (HDACi) in Myeloproliferative Neoplasms

Ann Diagn Pathol

Cutaneous Myeloid Dendritic Cell Dyscrasia: A Cutaneous Clonal Monocytosis Associated with Chronic Myeloproliferative Disorders and Peripheral Blood Monocytosis


Evaluation of Bone Marrow Morphology is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients

Blood Cancer J

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Risk Factors for Recurrences in a Cohort of 181 Patients

Clin Epidemiol

The Danish National Chronic Myeloid Neoplasia Registry

Biomed Res Int

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches

BMC Cancer

Myeloproliferative Neoplasms (MPNs) Have a Significant Impact on Patients’ Overall Health and Productivity

Osteoporosis International

Bone Mineral Density and Microarchitecture in Patients With Essential Thrombocythemia and Polycythemia Vera

Annuals of Hematology

Management of Extreme Thrombocytosis in Myeloproliferative Neoplasms: An International Physician Survey

Modern Pathology

The Myeloproliferative Neoplasms, Unclassifiable: Clinical and Pathological Considerations

PLoS One

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes

Mutation Research/Reviews in Mutation Research

Mutations of Myelodysplastic Syndromes (MDS): An Update

Journal of Blood Medicine

Ruxolitinib in the Treatment of Polycythemia Vera: Patient Selection and Special Considerations

Blood Reviews

The 2016 revision of WHO classification of myeloproliferative neoplasms


Activation of the Thrombopoietin Receptor by Mutant Calreticulin in CALR-Mutant Myeloproliferative Neoplasms

Current Hematologic Malignancy Report

The Use of Anagrelide in Myeloproliferative Neoplasms, With Focus on Essential Thrombocythemia

Clinical Lymphoma, Myeloma & Leukemia

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms

American Society of Clinical Oncology

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden

Journal of Medicinal Chemistry

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Clinical Lymphoma, Myeloma & Leukemia

How to Treat Essential Thrombocythemia and Polycythemia Vera

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.